All releases

Jan 12, 2016

Verseon Corporation (“Verseon” or the “Company”)

Verseon to Present Data on a New Class of Anticoagulants

FREMONT, Calif.—Verseon Corporation’s (AIM: VSN) David Kita, co-founder and Vice President of Research and Development, will present preclinical data on Verseon’s new class of anticoagulants at the 8th annual Biotech Showcase on January 12th, 2016 in San Francisco. Dr. Kita’s presentation will include recently obtained data from preclinical studies that demonstrate continuing and steady progress in Verseon’s anticoagulation program.

Dr. Kita commented on Verseon’s latest preclinical data. “The results we have obtained for our program represents compelling evidence that our drug candidates have lower bleeding risk than conventional therapies with equivalent or better therapeutic potential. This data will form an important part of our upcoming IND (Investigational New Drug) filings in the anticoagulant space.”

Verseon’s new class of oral, highly-selective, direct thrombin inhibitors show excellent results in preclinical efficacy studies and have pharmacokinetic profiles suitable for oral dosing. Furthermore, Verseon has demonstrated reduced risk of major bleeding for their drug candidates relative to current novel oral anticoagulants (NOACs).

About Verseon

Verseon is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.

- Ends -

For further information please contact

Verseon Corporation
Arthur Shmurun / Amy Thai +1 (510) 225 9000
Abchurch Communications Ltd (PR Advisers)
Jamie Hooper / Alex Shaw +44 (0) 20 7398 7719


This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook,” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions, and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors.